Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

Cancers, Год журнала: 2024, Номер 16(17), С. 2975 - 2975

Опубликована: Авг. 27, 2024

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.

Язык: Английский

---

Liquid Biopsy in Cancer Management: Integrating Diagnostics and Clinical Applications

Practical Laboratory Medicine, Год журнала: 2024, Номер unknown, С. e00446 - e00446

Опубликована: Дек. 1, 2024

Liquid biopsy is an innovative, minimally invasive diagnostic tool revolutionizing cancer management by enabling the detection and analysis of cancer-related biomarkers from bodily fluids such as blood, urine, or cerebrospinal fluid. Unlike traditional tissue biopsies, which require procedures, liquid offers a more accessible repeatable method for tracking progression, detecting early-stage cancers, monitoring therapeutic responses. The technology primarily focuses on analyzing circulating tumor cells (CTCs), DNA (ctDNA), other cancer-derived genetic materials. These provide critical information heterogeneity, mutation profiles, potential drug resistance. In clinical practice, has demonstrated its utility in identifying actionable mutations, guiding personalized treatment strategies, assessing minimal residual disease (MRD). While holds immense promise, challenges related to sensitivity, specificity, standardization remain. Efforts optimize pre-analytical analytical processes, along with establishment robust regulatory frameworks, are crucial widespread adoption. This abstract highlights transformative diagnosis, prognosis, monitoring, emphasizing role advancing oncology. Further research, trials, harmonization will be vital realizing full precision care.

Язык: Английский

---

Evaluating the Impact of Personalized Medicine on Cancer Treatment Outcomes

Journal of medical & health sciences review., Год журнала: 2025, Номер 2(1)

Опубликована: Янв. 15, 2025

Background: Personalized medicine has revolutionized cancer treatment by tailoring therapies to individual genetic and molecular profiles, enabling more targeted effective interventions. Advances in genomic technologies, such as Next-Generation Sequencing (NGS), biomarker analyses have allowed for precise identification of actionable mutations personalized strategies. However, understanding the clinical economic implications these approaches remains a priority optimize their application care. Objective: This study aims evaluate impact on outcomes, focusing progression-free survival (PFS), overall (OS), quality life, cost-effectiveness. By comparing patients receiving treatments with those undergoing standard care, seeks assess benefits challenges associated precision oncology. Methods: A retrospective cohort was conducted at tertiary centers, including diagnosed breast, lung, pancreatic who underwent Genomic profiling performed using NGS (e.g., PD-L1, EGFR, BRCA mutations). Outcomes PFS OS were analyzed Kaplan-Meier analysis Cox proportional hazards models. Cost-effectiveness evaluated through incremental cost-effectiveness ratio (ICER) calculations. Data sources included electronic health records (EHRs), registries, databases The Cancer Genome Atlas (TCGA). Results: Patients interventions demonstrated significantly improved compared (PFS: median 12.4 vs. 8.3 months; OS: 24.6 18.7 months, p < 0.05). Biomarker-driven exhibited highest efficacy, particularly among EGFR BRCA. revealed that medicine, while initially expensive, resulted better quality-adjusted life years (QALYs), making it economically viable long term. Conclusion: findings underscore transformative potential enhancing notable improvements life. high costs accessibility must be addressed ensure broader adoption. Future research should focus scaling exploring utility across diverse populations types.

Язык: Английский

---

MiRNA-155: A double-edged sword in colorectal cancer progression and drug resistance mechanisms

International Journal of Biological Macromolecules, Год журнала: 2025, Номер 299, С. 140134 - 140134

Опубликована: Янв. 20, 2025

Язык: Английский

---

Updates and current states on liposomal vehicles for tumor targeting: precision therapy in the spotlight

Cancer Nanotechnology, Год журнала: 2025, Номер 16(1)

Опубликована: Март 10, 2025

Язык: Английский

---

Recent advances in DNA nanotechnology for cancer detection and therapy: A review

International Journal of Biological Macromolecules, Год журнала: 2025, Номер unknown, С. 142136 - 142136

Опубликована: Март 1, 2025

Язык: Английский

---

From Gut to Glory: Unveiling the Microbiome’s Impact on Human Health

Regenerative Engineering and Translational Medicine, Год журнала: 2025, Номер unknown

Опубликована: Апрель 11, 2025

Язык: Английский

---

The prognostic significance of tumor-specific growth factor in colorectal cancer: an observation study

BMC Gastroenterology, Год журнала: 2025, Номер 25(1)

Опубликована: Апрель 21, 2025

The correlation between tumor-specific growth factor (TSGF) and the prognosis of colorectal cancer (CRC)has not been extensively studied. Research was designed to evaluate potential TSGF as a predictive marker for patients with CRC. serum quantified stratified into elevated/normal groups based on established threshold detected using rate method. log-rank test employed survival analysis 3-year overall (OS). Prognostic independence verified through Cox proportional hazards model. receiver operating characteristic (ROC) curves were plotted assess clinical application value TSGF. A total 2223 incorporated in our study. revealed that elevated levels associated poorer multivariate demonstrated an independent prognostic factor. signature covering T staging, N CEA, CA199 superior capability Area Under Curve (AUC) (Delong's p = 0.025). is correlating OS stage I-III CRC patients. Moreover, new including can effectively improve evaluation CRC, thereby contributing precision medication.

Язык: Английский

---

Integrated Synthesis, Characterization, and Computational Analysis of 1H Pyrrole-1,2,4-Oxadiazole Hybrids as Anticancer Agents

Journal of Molecular Structure, Год журнала: 2025, Номер unknown, С. 142575 - 142575

Опубликована: Май 1, 2025

Язык: Английский

---

KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications

Expert Opinion on Therapeutic Targets, Год журнала: 2025, Номер unknown, С. 1 - 23

Опубликована: Май 5, 2025

Despite decreasing trends in incidence, colorectal cancer (CRC) is still a major contributor to malignancy-related morbidities and mortalities. Groundbreaking advances immunotherapies targeted therapies benefit subset of CRC patients, with sub-optimal outcomes. Hence, there an unmet need design manufacture novel therapies, especially for advanced/metastatic disease. KRAS, the most highly mutated proto-oncogene across human malignancies, particularly pancreatic adenocarcinoma, non-small cell lung cancer, CRC, on-off switch governs several fundamental signaling cascades. KRAS mutations not only propel progression metastasis but also critically modulate responses therapies. We discuss impacts on CRC's tumor microenvironment describe strategies targeting its associated cascades mechanisms drug resistance. Drug development against has been challenging, mainly due structural properties (offering no appropriate binding site small molecules), critical functions wild-type non-cancerous cells, complex network downstream effector pathways (allowing malignant cells develop resistance). Pre-clinical early clinical data offer promises combining inhibitors

Язык: Английский

---